Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women

Journal of Clinical Pharmacology

Volumn 45, Issue 3, 2005, Pages 329-336

  Roy, Partha ^a   Jakate, Abhijeet S ^a   Patel, Alpita ^a   Abramowitz, Wattanaporn ^a   Wangsa, Julie ^b   Persiani, Stefano ^c   Kapil, Ram ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Rotta Research Laboratorium   (Italy)

Author keywords

Dexloxiglumide; Drug interactions; Oral contraceptives; Pharmacokinetics

Indexed keywords

CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DEXLOXIGLUMIDE; DRUG METABOLITE; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORELGESTROMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; LIQUID CHROMATOGRAPHY; MULTIPLE DRUG DOSE; NORMAL HUMAN; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TABLET; TANDEM MASS SPECTROMETRY;

ADULT; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MENSTRUAL CYCLE; MIDDLE AGED; NORGESTREL; PENTANOIC ACIDS; RECEPTORS, CHOLECYSTOKININ;

EID: 16844370522     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004272732     Document Type: Article

References (20)

1. Setnikar I, Bani M, Cereda R, et al. Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist. Arzneimittelforschung. 1987;37:703-707.
2. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides. 1994;15:731-755.
3. Ryan J. Motility of the gallbladder and biliary tree. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract. New York: Raven; 1987:695-721.
4. Chey W. Hormonal control of pancreatic exocrine secretion. In: Go VL, DiMagno P, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology, Pathobiology and Disease. New York: Raven; 1993:403-424.
5. Niederau C, Luthen R, Heintges T. Effects of CCK on pancreatic function and morphology. Ann N Y Acad Sci. 1994;713:180-198.
6. Grider JR. Role of cholecystokinin in the regulation of gastrointestinal motility. J Nutr. 1994;124(suppl):1334S-1339S.
7. Scarpignato C, Varga G, Corradi C. Effect of CCK and its antagonists on gastric emptying. J Physiol Paris. 1993;87:291-300.
8. Innis RB, Snyder SH. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA. 1980;77:6917-6921.
9. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun. 1993;193:204-211.
10. Corp ES, McQuade J, Moran TH, Smith GP. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res. 1993;623:161-166.
11. Webber C, Roth A, Persiani S, et al. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica. 2003;33:625-641.
12. Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther. 2002;40:198-206.
13. Hall M, Persiani S, Cheung YL, et al. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with humancytochiomes P450. Biopharm Drug Dispos. 2004;25:163-176.
14. Norgestimate/ethinyl estradiol (Ortho Tri-Cyclen Tablets, Ortho-McNeil Pharmaceuticals) monograph. In: Physician's Desk Reference. Montvale, NJ; 2003:2490-2497.
15. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18:472-484.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-680.
17. Inglis AM, Miller AK, Culkin KT, et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 2001;41:683-690.
18. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol. 2004;57:279-286.
19. Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf. 1993;9:21-37.
20. Back DJ, Breckenridge AM, Crawford FE, et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception. 1980;21:135-143.